New Indicaiton: DOCEtaxel as a Radiosensitizer in Head and Neck Cancer

  • Study

    Phase II/III, randomized, open-label study
    Cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC)
    Docetaxel-RT (n=180) vs. RT (n=176)

  • Efficacy

    2-year DFS: 42% vs. 30.3%, HR: 0.67, p=0.002
    Median locoregional failure-free survival: 12.4 vs. 5.9 mos, HR: 0.66, p=0.002
    mOS: 25.5 vs. 15.3 mos, HR: 0.74, p=0.035

  • Safety

    Grade 3 AEs: Odynphagia (52.5% vs. 33.5%), mucositis (49.7% vs 22.2%), dysphagia (49.7% vs. 33%)


    • J Clin Oncol 2023: 27 JAN

    Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation

    http://doi.org/10.1200/JCO.22.00980

    Reviewed by Elvin Chalabiyev, MD on Mar 15, 2023

    Altai Oncology App
    Download Altai Oncology App On App Store
    Download Altai Oncology App On Play Store
    • Chemotherapy Protocols
    • Summarized References
    • Oncology Drug Specs
    • TNM Staging
    • BSA, CrCl Calculator
    Back to top Drag